<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment
Image Overlay - Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

December 3, 2020

Parexel Biotech and Synairgen Collaborate on Phase III Trial for COVID-19 Treatment

Parexel Biotech has entered into a strategic collaboration with Synairgen. The two companies are working together on a phase III study of SNG001, an inhaled treatment for patients hospitalized with COVID-19. The trial aims to enroll 900 patients across 20 countries. Yourway has 21 strategically located depots around the world, to help advance all trials, at any scale, everywhere.

Back to Index
Media

Upcoming Events

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?